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1.

Introduction

In the field of medical diagnostic testing, the receiver operating characteristics(ROC)
curve has long been used as a standard statistical tool to assess the accuracy of tests that
yield continuous results. Previous research in the area focused mostly on estimating the
ROC curve, such as the popular empirical ROC curve, a nonparametric estimation of the
ROC curve and the LABROC procedure proposed by Metz et al. (1998).
Recently it has been recognized (Pepe, 1997 & 2000) that various factors can affect the
test performance beyond the disease status. Those factors include different test settings
and/or subject’s demographic data. One example is that for certain test whose test subjects
include both men and women or both younger and older people, its performance may vary
between men and women or between younger and older people. Pepe(2003, chapter 3) listed
several factors that can affect test performance, such as factors associated with test subject
or tester, test settings and severity of disease. It is therefore important to understand such
influence to determine the optimal and suboptimal conditions or populations to perform such
tests. If we find the test doesn’t perform well for certain condition or population, then we
may need to modify the test or even develop a new test for those situations. On the other
hand, if we find that a factor doesn’t influence test performance, we can relax the conditions
under which the test is performed.
Comparing performance between several different tests is a special case of modelling
covariate effects. When a new diagnostic test is developed, before it can be used in the
practice, frequently we need to compare it with an existing test to evaluate whether the
new test provides better discrimination between cases and controls. Under certain situations
(e.g., cost and invasiveness of the test), a new test is favored as long as it is proven to be
non-inferior to its closest competitor.
In this manuscript, we propose a linear regression framework to model covariate effect
on the ROC curve. In section 2 we describe the regression procedures for comparing two
1
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ROC curves. We illustrate our method using a pancreatic cancer data set in section 3. Using
linear regression procedure for general covariate effects modelling are presented in section 4.
We illustrate our method using an audiology data set in section 5. We give a summary and
some closing remarks in section 6.
2.

Comparing ROC Curves

2·1 Paired Tests versus Non-paired Tests
When comparing two diagnostic tests with respect to their performances, the study design
needs to be considered. Pepe(2003) introduced the concepts of paired tests versus nonpaired tests. If each individual in the population receives both tests, we call those tests
paired tests. If the results are from two independent populations of subjects, we call those
tests non-paired tests. Paired tests provide additional statistical challenge when we compare
their performances since we need to account for the correlation between the test results
derived from the same individual.
Since we routinely use the ROC curve to assess the performance of a continuous test,
naturally we compare the performances of two tests by comparing their corresponding ROC
curves. There are two main approaches to compare ROC curves: comparing summary
measures(e.g. AUC) of the ROC curves or using regression methods to compare the ROC
curves directly.
2·2 Comparing ROC curves by AUC statistics
The most popular approach to compare two ROC curves is based on the difference in their
empirical AUC values. Denote two curves by ROCA and ROCB , write the null hypothesis
as
H0 : ROCA = ROCB

(1)

dC e = AU
dC Ae − AU
dC Be
∆AU

(2)

Define
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dC e is defined to be the area under the emprical ROC curve.
where AU
q
d
dC e ) with a standard
The null hypothesis is tested by comparing ∆AU C e / var(∆AU
normal distribution, we call this test a Z-test based on empirical AUC statistics.
We need to point out that comparing AUC statistics is not equivalent to comparing
the ROC curves. Two ROC curves that have cross-overs in the middle can have same AUC
values, hence this approach is probably under-powered for settings when the two ROC curves
cross.
2·3 Compare ROC Curves by Regression
Pepe (1997, 2000) developed the ROC-GLM procedure which is the first regression based
method that can be used for ROC curves comparison. Pepe & Cai (2004) proposed another
regression method based on placement value concept. The common setting for comparing
ROC curves using regression is first to assume a parametric model for the ROC curves.
Although the binormal model is often used, we will present the methods using the more
general form as ROC(t) = g(α0 + α1 g −1 (t)). Define indicator variable Xtest as Xtest = 0 for
test A and Xtest = 1 for test B and assume the ROC curves for both tests have the following
parametric form:
ROCtest (t) = g(α0 + α1 g −1 (t) + βXtest + γXtest g −1 (t))

(3)

The parameter θ = (α0 , α1 , β, γ)T . This model specifies that for test A, its ROC curve is
ROC(t) = g(α0 + α1 g −1 (t))

(4)

and for test B, its ROC curve is
ROC(t) = g((α0 + β) + (α1 + γ)g −1 (t))

(5)

The underlying assumptions for equation (4) is that there exists an unknown monotone
increasing function hA , such that
hA (YD̄,A ) ∼ N (0, 1)
3
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and
hA (YD,A ) ∼ N (α0 /α1 , 1/α12 ).
Similarly, for test B, equation (5) assumes there exists an unknown monotone increasing
function hB , such that
hB (YD̄,B ) ∼ N (0, 1)
and
hB (YD,B ) ∼ N ((α0 + β)/(α1 + γ), 1/(α1 + γ)2 ).
Notice that hA and hB are not required to be the same.
To test the equivalency of tests A and B, the null hypothesis can be written as
H0 : (β, γ) = (0, 0)
Under H0 , if we can show

µ

β̂
γ̂

then the statistic

¶

µ
U=

(6)

D

−→ N (0, Σβγ )

β̂
γ̂

µ

¶0
Σ−1
βγ

β̂
γ̂

(7)

¶
(8)

where Σβγ is the covariance matrix for (β̂, γ̂), is distributed as a χ2 distribution with 2
degrees of freedom. In practice, we replace Σβγ with Σ̂βγ and if Σ̂βγ is consistent, we can test
the null hypothesis by comparing U with standard χ2 distribution with 2 degrees of freedom.
This method is first proposed by Metz& Kronman(1980).
d A (t)) and g −1 (ROC
d B (t)) are Gaussian
We can show in large samples, both g −1 (ROC
processes,
√

D
d A (t)) − g −1 (ROCA (t))) −→
nD̄ (g −1 (ROC
N (0, Σe,0 )

(9)

and
√

D

d B (t)) − g −1 (ROCB (t))) −→ N (0, Σe,1 )
nD̄ (g −1 (ROC

(10)

The proof of the above results and the definitions of Σe,0 and Σe,1 can be found in Zhang
(2004).
4

http://biostats.bepress.com/uwbiostat/paper253

Equation (9) and (10) imply g −1 (ROCA (t)) and g −1 (ROCB (t)) can be approximated by
d A (t)) and g −1 (ROC
d B (t)), respectively. Combining that with equation (4) and (5),
g −1 (ROC
d p,test ))
motivates the following estimation procedure. We first calculating the pairs (tp,test , ROC(t
for each test separately, let test = 0 for test A and test = 1 for test B.
1. Choose values for the boundary points a and b where 0 < a < b < 1. We recommend
a = 0.0001 and b = 0.9999 to ensure the maximal number of data points are included,
if the goal is to estimate the entire ROC curve. However, a and b can be chosen as any
values between 0 and 1 when only estimating part of the curve;
2. Divide the interval [a, b] into nD̄,test -1 equally spaced sub-intervals and let the midpoints
be denoted by Ttest = {tp,test };
3. For each tp,test , find the smallest threshold value cp,test , such that tp,test ≤ Fd
P F (cp,test ) =
PnD̄,test
I[YD̄j ,test ≥ cp,test ]/nD̄,test ;
j=1
PnD,test
d p,test ) = Td
4. Calculate ROC(t
P F (cp,test ) = i=1
I[YDi ,test ≥ cp,test ]/nD,test ;
d p,test )) if ROC(t
d p,test ) is either 0 or 1;
5. Exclude (tp,test , ROC(t
6. Let design matrix M be

µ 0
¶
M0 O 0
M =
(11)
M10 M10
¶
¶
µ
µ
1
...
1
...
1
...
1
...
where M00 =
, M10 =
and
g −1 (t1,0 ) ... g −1 (tp,0 ) ...
g −1 (t1,1 ) ... g −1 (tp,1 ) ...
O is a matrix with 0 in every entry.
0

d 1,0 ))...g −1 (ROC(t
d p,0 ))...)T , k = 0, 1;
7. Let Ỹ = (Y˜0 , Y˜1 ), where Y˜k = (g −1 (ROC(t
d p,test ), we can write
8. By the asymptotic distribution of ROC(t
.
d p,test )) =
g −1 (ROC(t
α0 + α1 g −1 (tp,test ) + βXtest + γXtest g −1 (tp,test ) + ²test

(12)

1

2
where nD̄,test
²test is normally distributed with mean 0 and asymptotic covariance matrix

Σe,test ;
5
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9. Our OLS estimator for θ is
θ̂ = (M 0 M )−1 M 0 Ỹ

(13)

Asymptotic distribution theory for the OLS estimator when the tests are not paired is
developed in Zhang(2004), in which the OLS estimator is shown to be unbiased and normally
distributed. Asymptotic theory for the OLS estimator when the tests are paired needs to be
developed in the future since joint asymptotic distribution for two paired ROC curves is not
yet available.
2·4 Simulation Studies
We generate data for paired tests under the null hypothesis (i.e. when (β, γ) = (0, 0)) to
address whether the χ2 test has correct size(type I error). The correlations between the
test results range from 0 to 0.75. The data is generated such that the models specified by
equations (4) and (5) hold. The variance calculation is based on the bootstrap method. For
comparison purpose, we will also assess whether the Z-test based on empirical AUC has the
right size.
Simulation settings are as the following: the correlation coefficient (ρ) is 0, 0.25, 0.5 or
0.75; the sample sizes are either nD,0 = nD,1 = 100 or nD̄,0 = nD̄,1 = 50; the parameter values
are (α0 , α1 , β, γ) = (1.2, 0.45, 0, 0). Data for test A are YD̄,0 ∼ N (0, 1) and YD,0 ∼ N ( αα01 , α12 )
1

2

and data for test B are YD̄,1 ∼ ρYD̄,0 +N (0, 1−ρ ) and YD,1 ∼

ρYD,0 +N ( αα01+β
+γ

1
−ρ αα10 , (α1 +γ)
2

−

ρ2
).
α21

For every 500 iterations, we calculated the numbers of iterations that produced p-values
less than 0.05, as that will be used as the criterion to reject the null hypothesis. Our target
for the rejection rate is 5%. Table 1 shows the rejection rates for both the χ2 test and Z test
along with the 95% confidence intervals. It shows that the χ2 test has the right size except
when ρ = 0.25, when the test is slightly conservative. On the contrary, the Z-test based on
the AUC statistics is slightly conservative when the tests are independent. Overall, these
simulation results suggest both tests are acceptable to use in practice.
6
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(Table 1 goes here)
We also investigated for comparing two ROC curves, whether the OLS approach is more
or less powerful than comparing the AUC values approach. Table 2 summaries the simulation
results. We found that when two ROC curves cross, the OLS method is more powerful. But
when the curves do not cross, AUC method is more powerful.
(Table 2 goes here)
3.

Application to Pancreatic Cancer Data Set

This dataset was first published by Wieand et al.(1989). It is a case-control study including
90 cases with pancreatic cancer and 51 controls that did not have cancer but who had
pancreatitis. Serum samples from each patient were assayed for CA-19-9, a carbohydrate
antigen, and CA-125, a cancer antigen, both of which are measured on the continuous positive
scale and higher values are more indicative of disease. A primary question to be addressed
by the study is to determine which of the two biomarkers better distinguishes cases from
controls. We will compare their corresponding ROC curves to address this question.
Since CA-125 and CA-19-9 are paired tests, we use the bootstrap variances in the inference. The distribution of the test results are closer to normal at the log scale, hence we
calculated the correlation coefficients at that scale, which are -0.141 in the control group
and 0.142 in the diseased group. Table 3 shows the parameter estimates when we compare
the curves in the entire range of (0, 1). Data is analyzed by letting g = Φ and using the
boundary value (a, b)= (0.0001, 0.9999). We choose CA-125 to be test 1 and CA-19-9 to
be test 2, therefore, (α0 , α1 ) is the parameter for the CA-125 ROC curve, (α0 + β, α1 + γ) is
the parameter for the CA-19-9 ROC curve and (β, γ) measures the difference between the
two curves. After adjusting for multiple comparisons by Bonferroni method, we found the
p value for γ is 0.0067 < 0.025, but the p value for β is 0.0751 > 0.025, which means that
the slopes of the two curves are statistically significantly different from each other but the
intercepts of the two curves are not. The p value from the χ2 test is 0.0019, which shows
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overall the curves are different. We also calculated the p value by comparing empirical AUC
statistics, which is 0.007, hence we reach same conclusion by both method, but the p value
from AUC-based test is larger, which can be explained by the fact that the two ROC curves
have a cross in the end when t is close to 0.8, which is the setting when AUC-based test may
not be as powerful as OLS-based test.
(Table 3 goes here)
Figure 1 shows the OLS-fitted ROC curves as well as the empirical curves for both CA125 and CA-19-9. The fitted curves follows the empirical curves well, suggesting a good
fitting.
(Figure 1 goes here)
Table 4 shows the parameter estimates when we are comparing only the part of curves
when the false positive fraction is less than 20%. Data is analyzed by letting g = Φ and using
the boundary value (a, b)= (0.0001, 0.2). The p value for γ is slightly over 0.025(0.032) and
the p value for β is not significant(p = 0.463). The p value from the χ2 test is p < 0.0001.
The smaller p value here reflects the fact that the difference between the two curves are more
prominent in the lower part of the curves.
(Table 4 goes here)
A test based on the difference in empirical partial AUC statistics found the difference is statistically significantly different from 0 based on bootstrap distribution with p <
0.001(Pepe 2003). Again this p-value is slightly larger than the p-value based on the OLS
method, suggesting the test based on the summary measure is not as powerful as the test
based on comparing the actual curves. Figure 2 shows the OLS-fitted partial ROC curves
as well as the empirical curves for both CA-125 and CA-19-9. The fitted curves follows the
empirical curves well, suggesting a good fitting.
(Figure 2 goes here)
ROC-GLM method yields estimates for β = 0.23(se = 0.71) and γ = −0.91(se =
0.46)(Pepe 2000). Placement value regression method yields estimates for β = 0.02(se =
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0.64) and γ = −0.98(se = 0.40)(Pepe & Cai 2002). Hence OLS method is more efficient
than both ROC-GLM and PV regression methods. Notice although the estimates for β and
γ are quite different across all three methods, because of the large se, those estimates are
not inconsistent with each other.
To make conclusions about relative efficiency between the OLS method and the ROCGLM method, we simulated data under the fitted model as shown in Table 3 where (α0 , α1 , β, γ)
= (0.717, 0.986, 0.485, -0.518) and we chose the correlation coefficients to be the same as
the values found in the pancreatic cancer data; ρ = −0.141 for the control group ρ = 0.142
for the diseased group. The simulation results suggested that the OLS estimator is more
efficient than the ROC-GLM estimator under this setting. The variance for (α̂0 , α̂1 , β̂, γ̂) is
(0.191, 0.130, 0.266, 0.162) for the OLS estimator and (0.193, 0.139, 0.269, 0.171) for the
GLM estimator.
4.

Modeling Covariate Effects

The covariates that potentially influence the test performance can be either categorical or
continuous. Examples of categorical covariates include gender of the test subjects and different test settings. Examples of continuous covariates include age of the test subjects.
Although it is natural to model the covariate effects on its given scale, by modeling a continuous covariate, we usually make a stronger model assumption than modeling a categorical
covariate.
To make this idea clear, consider the existing methodology to evaluate covariate effects on
test performance using regression models for the ROC curve. The common feature for those
methods is that they all assume a parametric model for the ROC curve. Those methods
usually include the continuous covariates as linear terms, by doing that, they make an
additional assumption that the ROC curves are “linearly” related, i.e. the tests are either
getting progressively better or worse when the covariates values are getting larger. This is a
pretty strong assumption and may not be appropriate for all covariates. For example, a test

9

Hosted by The Berkeley Electronic Press

may perform best in the young adults but not so good in children and elderly people. Hence
the relationship between the test performance(ROC curve) and the age is not linear. By
modeling the covariates as a categorical variable, however, we make less assumption about
the directions of the covariates effect.
Although we argue here for the advantage of using categorical covariate in the model,
interpretation from the model that uses continuous covariates is usually simpler. It is not
our intention to discourage the use of continuous covariates in the model all together.
4·1 Uncorrelated versus Correlated Subsets
Suppose there are N categorical covariates available to us and we wish to include all of
them in our model. Those covariates essentially partition the entire data into K subsets,
each subset represents an unique combination of those N covariates. Those subsets could
be correlated or uncorrelated. For example, when the covariate is the test setting and each
individual receives tests under more than one setting, then the subsets would be correlated.
If test results from those subsets are uncorrelated, this is analogous to the non-paired tests
situation we discussed in the previous chapter. If, however, the test results from different
subsets are correlated, we have “paired-tests” situation. Inference for uncorrelated and
correlated subsets is a generalization of the inference for non-paired and paired tests, where
in the latter case, the number of covariate is one and the number of subsets is two.
4·2 Regression Model for Covariate Effects
Assume there are N categorical covariates, resulting in K unique combination. Partition the
data into the corresponding K subsets.
For subset 1(reference subset), assume
g −1 (ROC1 (t)) = β1 + γ1 g −1 (t)

(14)

For subset k, k = 2, ..., K, assume
g −1 (ROCk (t)) = β1 + γ1 g −1 (t) + βk + γk g −1 (t)

(15)
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http://biostats.bepress.com/uwbiostat/paper253

Hence βk is the difference in the intercept parameter of the ROC curves for subset k and
the reference subset and γk is the difference in the slope parameter of the ROC curves for
subset k and the reference subset.
The underlying assumptions for equation (14) is that there exists an unknown monotone
increasing function h1 , such that
h1 (YD̄,1 ) ∼ N (0, 1)
and
h1 (YD,1 ) ∼ N (β1 /γ1 , 1/γ12 ).
Similarly, for subsequent subset k, k = 2, 3, ..., K, equation (15) assumes there exists an
unknown monotone increasing function hk , such that
hk (YD̄,k ) ∼ N (0, 1)
and
hk (YD,k ) ∼ N ((β1 + βk )/(γ1 + γk ), 1/(γ1 + γk )2 ).
Notice that hk s are not required to be the same for different k. The parameter we need to
d k (t)) for
estimate here is θ = (β1 , γ1 , ..., βK , γK )T . We can show in large samples, g −1 (ROC
k = 1, 2, ...K are Gaussian processes,
√

D
d1 (t)) − g −1 (ROC1 (t))) −→
N (0, Σe,1 )
nD̄,1 (g −1 (ROC

(16)

D
dk (t)) − g −1 (ROCk (t))) −→
nD̄,k (g −1 (ROC
N (0, Σe,k )

(17)

and
√

The proof of the above results and the definitions of Σe,1 and Σe,k can be found in Zhang
(2004).
4·3 Estimating Procedures
d k (t)). ComEquation (16) and (17) imply g −1 (ROCk (t)) can be approximated by g −1 (ROC
bining that with equation (14) and (15), motivates the following estimation procedure:
11
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d pk )) for each
1. Follow the steps 1-5 from section 2.3 to calculate the pairs (tpk , ROC(t
subset separately;
2. Let design matrix M be


M1 O O
 M2 M2 O

M =
 M3 O M3
 .
.
.
MK O O
µ
¶
1
...
1
...
0
where Mk =
and O
g −1 (t1,k ) ... g −1 (tpk ) ...


.. O
.. O 

.. O 

..
. 
.. MK

(18)

is a matrix with 0 in every entry.

d 1k ))...g −1 (ROC(t
d pk )))T ;
3. Let Ỹ = (Ỹ1 , Ỹ2 , ..., ỸK )T and Y˜k = (g −1 (ROC(t
4. Our linear model is:
for subset 1,
.
d 1 (tp,1 )) =
g −1 (ROC
β1 + γ1 g −1 (tp,1 ) + ²1
where

√

(19)

nD̄,1 ²1 is normally distributed with mean 0 and asymptotic covariance matrix

Σr,1 ;
For subset k, k = 2, 3, ..., K
.
d k (tp,k )) =
g −1 (ROC
β1 + γ1 g −1 (tp,k ) + βk + γk g −1 (t) + ²k
where

√

(20)

nD̄,k ²k is normally distributed with mean 0 and asymptotic covariance matrix

Σr,k ;
5. Our OLS estimator for θ is
θ̂ = (M 0 M )−1 M 0 Ỹ

(21)

Asymptotic distribution theory for the OLS estimator when the subsets are not correlated
is developed in Zhang(2004), in which the OLS estimator is shown to be unbiased and
normally distributed. Asymptotic theory for the OLS estimator when the data are correlated
needs to be developed in the future since joint asymptotic distribution for correlated multiple
ROC curves is not yet available.
12
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4·4 Covariate Consideration
We present our method by assuming all covariates are categorical. If we want to include
continuous covariate Z in the model, we need to have ŜD̄,Z and ŜD,Z for all possible values
of Z. Since it is impossible to do this non-parametrically, we are left with the choice of
semiparametric and parametric modelling of ŜD̄,Z and ŜD,Z . Semiparametric and parametric
modeling of ŜD̄,Z has been proposed by several authors(see Pepe(2003) for a comprehensive
review), it is possible to impose a semiparametric or parametric model on ŜD,Z as well. We
need to be more carefully here though, since for certain disease, the disease status makes the
distribution of test results more irregular and unpredictable.
If certain covariate value is given on the continuous scale, we need to categorize it into
appropriate groups first before applying OLS method. The categorization should depend on
both the question of interest(i.e. scientific relevance) and the actual data, i.e., we need to
make sure there are sufficient observations in each group. Based on our simulation studies,
a sample size where the minimum of nD and nD̄ is at least 50 seems sufficient.
Least squares approach can also accomodate disease-specific covariates. For example,
suppose there is a covariate for disease severity that has two categories: mild and severe.
Then for each level of severity, we can just use the non-diseased observation as the reference
population and calculate the corresponding T P F and F P F .
5.

Application to DPOAE Data Set

The DPOAE data set was first published by Stover et.al (1996). DPOAE stands for distortion product otoacoustic emission, which is an audiology test used to separate normalhearing from hearing-impaired ears. We only analyze a subset of the entire data set. The
test is administrated under 9 different auditory stimulus conditions with three levels of frequency(1001, 1416 and 2002 Hz) and three levels of intensity(55, 60 and 65 dB SPL). A total
of 210 subjects were included in the study. The subjects were considered cases with hearing
impairment at a given frequency if their audiometric threshold exceeds 20dB HL measured
13
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by a behaviour test(gold standard). Each subject was tested in only one ear. Test result is
the negative signal-to-noise ratio, -SNR, with higher value being more indicative of hearing
impairment. The objective of the analysis is to determine the optimal setting for the clinical
use of DPOAE to separate normal from hearing-impaired ears, but bear in mind an ear may
be determined to be hearing impaired or normal at different frequencies.
We partition the data into nine subsets, corresponding to the nine test settings. Since
each subject is tested under more than one setting, those subsets are correlated, therefore we
will use bootstrap method to estimate the variance. The bootstrap is done by sampling the
subjects with replacement and use all the test results associated with each sampled subject.
We apply the OLS method to the DPOAE data set using the models specified in (19)
and (20). Data is analyzed by letting g = Φ and using the boundary value (a, b)= (0.0001,
0.9999). We choose the reference subset (subset 1) to be the test setting with frequency value
of 1001Hz and intensity value of 55 dB SPL. The standard error is estimated from bootstrap
method. (β1 , γ1 ) is the intercept and slope estimates for the ROC curve for setting (1001,
55) and the subsequent βk and γk , with k = 2, .., 9, represent the differences in the intercept
and slope parameters of the ROC curves between subset k and subset 1. We found none of
the γ̂k is statistically significantly different from 0 (P value> 0.5).
0

We also develop a χ2 test statistic γ̂ Σ̂γ γ̂, where γ = (γ2 , ...γ9 ) and Σ̂γ is the estimated
covariance matrix of γ̂. Write the null hypothesis as H0 : γ = 0 and compare the above
statistic with a χ2 distribution with 8 degrees of freedom gives a P-value of 0.84, which
is consistent with the result from testing the significance of each γk separately that the
interaction terms in model (4.2) are not statistically significant.
We re-analyze the data with the interaction terms omitted and Table 5 summarizes the
results. From Table 5, we can see within the nine test settings, the setting (1416, 55)
generates a ROC curve with the largest intercept estimate and the difference between it
and the intercept estimate for the reference ROC curve (β4 ) is statistically significant with
a P-value 0.0041. The P-value for other parameters(β2 , β3 , β5 to β9 ) are not significant.

14
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The estimated ROC curve for setting (1416, 55) is ROC(t) = Φ(2.54 + 0.82Φ−1 (t)) with
estimated AUC value of 0.975, which is the largest among all settings. We know the larger
the AUC value, the better the test in discrimating cases versus controls. From the sign of
the estimates, we can see the performance of the test gets worse with the increasing intensity
when we fix the frequency value. This analysis suggests (1416Hz, 55 dB SPL) is a better
test setting than the reference setting.
(Table 5 goes here)
We have also analyzed the data by ROC-GLM method without the interaction terms and
Table 6 summarizes the results.
(Table 6 goes here)
Table 5 and 6 show that OLS and ROC-GLM methods generate similar estimates for
parameters β and γ. They have similar standard error estimates and inference based on
either method is the same that both suggest setting (1416, 55) constitutes a better test than
the reference setting (1001,55).
Figure 3 shows the empirical and the OLS-fitted ROC curves for all nine test settings.
It shows the fitted ROC curves follows the empirical ROC curves very well, indicating good
fittings.
(Figure 3 goes here)
6.

Discussion

This manuscript addresses statistical methods to compare diagnostic tests performance and
more generally, assess potential covariate effects on the test performance. Often a new
developed test is being compared with an existing test to determine whether the new test
has any advantage. If each individual in the population receives both tests, those tests are
called paired tests; otherwise, they are called non-paired tests. We demonstrate how to use
linear regression method(OLS) to compare ROC curves by assuming a parametric model for
each curve and test the difference in the intercept and slope parameters of the curves. A
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χ2 test statistic is developed under the regression framework to test the overall difference
in the two curves. The asymptotic distribution theory for the OLS estimators is developed
when the two tests are non-paired, in which the estimators are shown to be consistent and
normally distributed asymptotically.
Summary measures like AUC or pAUC statistics can be used to compare two ROC curves
as well. Although intuitive, this approach is underpowered in the situation when the two
curves have cross-overs. Simulation studies are carried out to assess the size of the χ2 test as
well as the size of the Z-test based on the empirical AUC statistics. We find both tests are
slightly conservative in some cases but are suitable to be used in practice. We illustrate our
method using the pancreatic cancer data set and find the two biomarkers are statistically
significantly different from each other and CA-19-9 is a more accurate test. Standard error
estimates for the OLS estimator is smaller than the estimates from other regression based
methods when we compare partial ROC curves.
Various factors can affect a test performance beyond the disease status, which motivates
incorporating the covariate information into the ROC curve analysis. We demonstrate how to
use linear regression to estimate covariate effects. We illustrate our method on an audiology
test(DPOAE) data set, in which we show that OLS and ROC-GLM estimators have similar
standard error estimates in estimating the ROC curve parameters.
One topic left for comparing two ROC curves is the development of asymptotic theory
for the OLS estimators when the two tests are paired. What is needed here is the joint
distribution of two correlated empirical ROC curves. If shown that they have a bivariate
normal distribution asymptotically, the asymptotic distribution theory for the OLS estimator
can be approved easily.
For covariate effects modelling, we have only included categorical covariates in our linear
regression model. We would like to explore whether continuous covariates can be accomodated in the model as well. One possible approach is for a given covariate Z, using either
semiparametric or parametric model to model ŜD,Z in addition to modeling ŜD̄,Z (Pepe,
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2003).
In summary, the proposed linear regression framework provides an unified approach for
the ROC curve analysis. It can be used to estimate or compare ROC curves, as well as
incorporate covariate information in the model. The application of ROC curve goes beyond
the medical diagnostic field and it can be used for evaluating any discrimination tools. It is,
and will continue to be an important and exciting area to engage in research.
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Table 1: Rejection rates and confidence intervals for χ2 test based on the OLS estimator and
Z-test based on the empirical AUC statistics. Results are based on 500 simulation runs.
ρ
χ2 test
Z-test
0
4.8%(2.9%,6.7%) 3.2%(1.7%,4.7%)
0.25 3.2%(1.7%,4.7%) 6.4%(4.3%,8.5%)
0.5 5.0%(3.1%,6.9%) 6.0%(3.9%,8.1%)
0.75 5.0%(3.1%,6.9%) 5.4%(3.4%,7.4%)

Table 2: Power of the OLS method and the AUC method. Results are based on 1000
simulation runs. (α0 , α1 )=(0.5,0.75) and ρ = 0.
OLS AUC Curves cross
(β, γ)
(0.1, 0)
0.046 0.069
No
(0.2, 0)
0.429 0.454
No
(0.1, −0.25) 0.318 0.112
Yes

Table 3: Comparison of the whole ROC curves for CA-19-9 and CA-125 from the pancreatic
cancer data set by the OLS method.
Parameter Estimate SE(bootstrap)
0.206
α0
0.717
α1
0.986
0.165
β
0.485
0.273
γ
-0.518
0.191

P value
0.0005
< 0.0001
0.0751
0.0067

Table 4: Comparison of the partial ROC curves for CA-19-9 and CA-125 when the false
positive fractions are below 20%.
Parameter Estimate SE(bootstrap)
0.565
α0
0.594
α1
1.030
0.306
β
0.455
0.619
γ
-0.687
0.321

P value
0.293
0.0008
0.463
0.032
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Table 5: Covariates effects on the ROC curves estimated by the the OLS method for the
DPOAE test.
(Frequency,
intensity)
Parameter Estimate
(1001,55)
β1
1.73
(1001,55)
γ1
0.82
(1001,60)
β2
-0.20
(1001,65)
β3
-0.36
(1416,55)
β4
0.81
(1416,60)
β5
0.36
(1416,65)
β6
0.19
(2002,55)
β7
0.47
(2002,60)
β8
0.42
(2002,65)
β9
0.10

Std.Err
0.26
0.12
0.14
0.19
0.28
0.29
0.28
0.29
0.28
0.27

P value
< 0.0001
< 0.0001
0.1455
0.0607
0.0041
0.2172
0.5064
0.1052
0.1293
0.7019

AUC
0.910
0.882
0.855
0.975
0.947
0.931
0.956
0.952
0.921

Table 6: Covariates effects on the ROC curves estimated by the ROC-GLM method for the
DPOAE test.
(Frequency,
intensity)
Parameter Estimate
(1001,55)
β1
1.84
(1001,55)
γ1
0.95
(1001,60)
β2
-0.21
(1001,65)
β3
-0.32
(1416,55)
β4
0.82
(1416,60)
β5
0.39
(1416,65)
β6
0.18
(2002,55)
β7
0.41
(2002,60)
β8
0.46
(2002,65)
β9
0.06

Std.Err
0.29
0.13
0.13
0.19
0.30
0.31
0.30
0.28
0.29
0.27

P value
< 0.0001
< 0.0001
0.1097
0.1029
0.0073
0.2022
0.5436
0.1496
0.1082
0.8221
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Figure 1: The OLS-fitted ROC curves along with the empirical curves for CA-125 and CA19-9

0.0

Top: CA-19-9
Bottom: CA-125
0.0

0.05

0.10

0.15

0.20

False Positive Fraction

Figure 2: The OLS-fitted partial ROC curves along with the empirical curves for CA-125
and CA-19-9
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Figure 3: The empirical and fitted ROC curves for DPOAE data set
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